KNSA_OUT_1 [2025-04-29 09:58:03 -0400] 5551 Bytes | 1518 tokens | Cum: 1518 tkns (18.98% of 8k)
==========================================================================

By the grace of fortune and the swing of fate, Kiniksa Pharmaceuticals International (KNSA) hath moved from $21.47 to $24.99. 'Tis 9:58 AM on Tue Apr 29, 2025. We must needs inquire—doth this path lead unto riches or ruin?

--- COMPANY PROFILE ---
Company: Kiniksa Pharmaceuticals International (KNSA)
IPO: 2018-05-24 (6 Years Ago)
Market Cap: $1,390,410,754
Shares Outstanding: 42,010,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Here’s a list of headlines for Kiniksa Pharmaceuticals International:

Today 08:35AM - Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
07:30AM - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
02:10AM - Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ...
02:10AM - Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For
Apr-24-25 04:01PM - Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Apr-22-25 07:21AM - Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Apr-21-25 09:54AM - uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
Apr-10-25 09:31AM - Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
Apr-08-25 09:40AM - Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Apr-04-25 09:55AM - Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
Mar-27-25 08:35AM - ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
Mar-19-25 09:55AM - How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
Mar-14-25 05:51AM - 3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Mar-06-25 08:23AM - Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?
Mar-04-25 12:20PM - Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Mar-04-25 12:20PM 03:05AM - Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Mar-03-25 09:55AM - Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
Mar-02-25 11:58AM - Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?
Feb-25-25 08:45AM - Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
Feb-25-25 08:45AM 07:30AM - Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
Feb-25-25 08:45AM 07:29AM - Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
Feb-20-25 04:01PM - Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-14T09:51:00Z - 3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
B2 - 2025-02-20T21:01:00Z - Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
B3 - 2025-01-14T18:00:00Z - Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
B4 - 2024-11-04T18:00:00Z - Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
B5 - 2024-06-17T12:30:00Z - Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
B6 - 2024-06-04T20:01:00Z - Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Kiniksa Pharmaceuticals International (KNSA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

KNSA_OUT_3 [2025-04-29 09:58:04 -0400] 1036 Bytes | 261 tokens | Cum: 1781 tkns (22.26% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T12:06:58Z - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution ...
A2 - 2025-04-29T11:57:13Z - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution...
A3 - 2025-04-29T11:30:00Z - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution ...
A4 - 2025-04-29T11:30:00Z - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution...
A5 - 2025-04-29T11:30:06Z - Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KNSA_OUT_5 [2025-04-29 09:58:05 -0400] 1183 Bytes | 346 tokens | Cum: 2129 tkns (26.61% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | Taiwan News | Apr. 29, 2025 19:30**Date: 2025-04-29Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6097696- ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -

- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -

- KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -

- Current operating plan expected to remain cash flow positive on an annual basis -

- Conference call and webcast scheduled for 8:30 am ET today -

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_7 [2025-04-29 09:58:06 -0400] 1182 Bytes | 265 tokens | Cum: 2396 tkns (29.95% of 8k)
==========================================================================

Showing A1 (chunk 2 of 17): developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported first quarter 2025 financial results and recent portfolio execution.

"Kiniksa continues to drive strong growth with ARCALYST. In the first quarter of 2025, our robust commercial execution resulted in a meaningful increase in active commercial patients, driven by increases to the prescriber base, longer average total duration of treatment, and changes to Medicare Part D. As a result of strong first quarter performance, we are increasing our expected 2025 ARCALYST net sales to between $590 and $605 million from our previous guidance of between $560 and $580 million," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "Also, we are excited about the potential of KPL-387 to be an additional treatment option for patients by enabling dosing

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_9 [2025-04-29 09:58:07 -0400] 1184 Bytes | 302 tokens | Cum: 2700 tkns (33.75% of 8k)
==========================================================================

Showing A1 (chunk 3 of 17): with a single monthly subcutaneous injection in a liquid formulation. We remain on track to initiate the KPL-387 Phase 2/3 recurrent pericarditis trial in the middle of this year."

Portfolio Execution

ARCALYST (IL-1α and IL-1β cytokine trap)

ARCALYST net product revenue was $137.8 million for the first quarter of 2025.Since launch, more than 3,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis.As of the end of the first quarter of 2025, average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 30 months, compared to approximately 27 months as of the end of the fourth quarter of 2024.

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

Pharmacokinetic data from the single ascending dose portion of the Phase 1 study support the development plan for KPL-387; Kiniksa plans to initiate a Phase 2/3 clinical trial in mid-

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_11 [2025-04-29 09:58:07 -0400] 1182 Bytes | 301 tokens | Cum: 3003 tkns (37.54% of 8k)
==========================================================================

Showing A1 (chunk 4 of 17): 2025. The trial will evaluate KPL-387 in recurrent pericarditis, with a target profile of monthly subcutaneous (SC) dosing in a liquid formulation. The company expects data from the Phase 2 portion of the trial in the second half of 2026.

KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist)

Kiniksa is conducting Investigational New Drug (IND)-enabling development activities with a target profile of quarterly SC dosing.

Financial Results

Total revenue for the first quarter of 2025 was $137.8 million, compared to $79.9 million for the first quarter of 2024. Kiniksa did not record any license and collaboration revenue for the first quarter of 2025, compared to $1.0 million for the first quarter of 2024. Total operating expenses for the first quarter of 2025 were $124.5 million, compared to $96.4 million for the first quarter of 2024. Total operating expenses for the first

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_13 [2025-04-29 09:58:08 -0400] 1182 Bytes | 301 tokens | Cum: 3306 tkns (41.33% of 8k)
==========================================================================

Showing A1 (chunk 5 of 17): quarter of 2025 included $43.8 million in collaboration expenses, which are driven by ARCALYST collaboration profitability, compared to $20.8 million for the first quarter of 2024.Total operating expenses for the first quarter of 2025, included $7.7 million in non-cash, share-based compensation expense, compared to $7.2 million for the first quarter of 2024. Net income for the first quarter of 2025 was $8.5 million, compared to a net loss of $17.7 million for the first quarter of 2024.As of March 31, 2025, Kiniksa had $268.3 million of cash, cash equivalents, and short-term investments and no debt.

Financial Guidance

Kiniksa expects 2025 ARCALYST net product revenue of between $590 million and $605 million, compared to prior guidance of between $560 million and $580 million.Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.Kiniksa continues to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_15 [2025-04-29 09:58:09 -0400] 1182 Bytes | 254 tokens | Cum: 3562 tkns (44.52% of 8k)
==========================================================================

Showing A1 (chunk 6 of 17): monitor potential implications of tariffs on pharmaceuticals imported into the United States. ARCALYST is currently manufactured in the United States by Regeneron Pharmaceuticals. Kiniksa has been in the process of transferring drug substance manufacturing to Samsung Biologics in South Korea and believes any future impact to ARCALYST gross margin would be immaterial, limited only to the cost of drug substance imported into the United States.

Conference Call Information

Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2025, to discuss first quarter 2025 financial results and recent portfolio execution.Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_17 [2025-04-29 09:58:10 -0400] 1183 Bytes | 275 tokens | Cum: 3839 tkns (47.99% of 8k)
==========================================================================

Showing A1 (chunk 7 of 17): with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa's website. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa's portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

About ARCALYST

ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_19 [2025-04-29 09:58:10 -0400] 1183 Bytes | 294 tokens | Cum: 4135 tkns (51.69% of 8k)
==========================================================================

Showing A1 (chunk 8 of 17): nterleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

ARCALYST may affect your immune system and can lower the abilit

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_21 [2025-04-29 09:58:11 -0400] 1186 Bytes | 283 tokens | Cum: 4420 tkns (55.25% of 8k)
==========================================================================

Showing A1 (chunk 9 of 17): y of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.Medicines that affect the imm

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_23 [2025-04-29 09:58:12 -0400] 1183 Bytes | 283 tokens | Cum: 4705 tkns (58.81% of 8k)
==========================================================================

Showing A1 (chunk 10 of 17): une system may increase the risk of getting cancer.Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, talk to your doctor and see the Product Information.

About KPL-387

KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines I

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_25 [2025-04-29 09:58:12 -0400] 518 Bytes | 158 tokens | Cum: 4865 tkns (60.81% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-23 8-K Item 9.01. Fin Stmnts and Exhibits.

(d) Exhibits

Exhibit No. Description 10.1 * KPL-387 Long-Term Incentive Plan for Exec Offs 10.2 Form of Milestone 1 Cash Award Grant Notice and Agrmt under the KPL-387 Long-Term Incentive Plan 10.3 Form of Milestone 2 ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KNSA_OUT_27 [2025-04-29 09:58:13 -0400] 1181 Bytes | 326 tokens | Cum: 5193 tkns (64.91% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description 10.1 * KPL-387 Long-Term Incentive Plan for Executive Officers 10.2 Form of Milestone 1 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 10.3 Form of Milestone 2 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 10.4 Form of Milestone 1 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 10.5 Form of Milestone 2 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 10.6 Form of Milestone 1 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 10.7 Form of Milestone 2 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

* Portions of the exhibit h

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_29 [2025-04-29 09:58:14 -0400] 358 Bytes | 103 tokens | Cum: 5298 tkns (66.22% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): ave been redacted in compliance with Regulation S-K Item 601(b)(10)(iv)....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KNSA_OUT_31 [2025-04-29 09:58:21 -0400] 9415 Bytes | 2651 tokens | Cum: 7951 tkns (99.39% of 8k)
==========================================================================

This is our set of metrics for Kiniksa Pharmaceuticals International.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 146,688 | Perf Month: 7.42% | Option/Short: Yes / Yes | Sales Y/Y TTM: 56.60% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 624.97K | Perf Quarter: 22.91% | Short Float: 8.19% | ROE: -9.85% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 2.96 | Index: RUT | Short Ratio: 5.31 | ROI: -9.68% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 69.58 | Market Cap: 1.81B | Short Interest: 3.32M | Sales Surprise: -0.71% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 1.19 | Shs Outstand: 41.88M | Beta: 0.11 | EPS Surprise: -597.93% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: 19.49% | Shs Float: 40.47M | Sales Q/Q: 46.93% | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: 16.60% | Inst Own: 56.44% | Sales past 5Y: 110.12% | Earnings: Apr 29 BMO |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: 9.93% | Insider Own: 44.57% | Employees: 315 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 23.89% | Insider Trans: -1.02% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Kiniksa Pharmaceuticals International officers or majority shareholders (if available).

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Moat Ross (CHIEF COMMERCIAL OFFICER) on 2025-04-21
- Class A Ordinary Share: 18259 shares at $20.29 (D) Footnote: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Tessari Eben (CHIEF OPERATING OFFICER) on 2025-04-14
- Class A Ordinary Share: 7000 shares at $3.8 (D) Footnote: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- Class A Ordinary Share: 5579 shares at $20.19 (D) Footnote: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- Class A Ordinary Share: 6421 shares at $20.74 (D) Footnote: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- Share Option: 7000 shares at $0 (D) Footnote: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Megna Michael R (CHIEF ACCOUNTING OFFICER) on 2025-04-07
- Class A Ordinary Share: 3933 shares at $N/A (D)
- Class A Ordinary Share: 1666 shares at $20.28 (D)
- Restricted Share Unit: 3933 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Moat Ross (CHIEF COMMERCIAL OFFICER) on 2025-04-07
- Class A Ordinary Share: 2477 shares at $N/A (D)
- Class A Ordinary Share: 727 shares at $20.28 (D)
- Restricted Share Unit: 2477 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Paolini John F. (CHIEF MEDICAL OFFICER) on 2025-04-07
- Class A Ordinary Share: 2498 shares at $N/A (D)
- Class A Ordinary Share: 734 shares at $20.28 (D)
- Restricted Share Unit: 2498 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Patel Sanj K (CHAIRMAN & CEO) on 2025-04-07
- Class A Ordinary Share: 9992 shares at $N/A (D)
- Class A Ordinary Share: 4832 shares at $20.28 (D)
- Restricted Share Unit: 9992 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Ragosa Mark (CHIEF FINANCIAL OFFICER) on 2025-04-07
- Class A Ordinary Share: 2694 shares at $N/A (D)
- Class A Ordinary Share: 1303 shares at $20.28 (D)
- Restricted Share Unit: 2694 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Tessari Eben (CHIEF OPERATING OFFICER) on 2025-04-07
- Class A Ordinary Share: 2726 shares at $N/A (D)
- Class A Ordinary Share: 801 shares at $20.28 (D)
- Restricted Share Unit: 2726 shares at $0 (D)

Inside Trans: Kiniksa Pharmaceuticals International, plc (KNSA) by Paolini John F. (CHIEF MEDICAL OFFICER) on 2025-04-01
- Class A Ordinary Share: 1624 shares at $N/A (D)
- Class A Ordinary Share: 1750 shares at $N/A (D)
- Class A Ordinary Share: 477 shares at $21.77 (D)
- Class A Ordinary Share: 514 shares at $21.77 (D)
- Share Option: 39364 shares at $0 (D)
- Restricted Share Unit: 9828 shares at $0 (D)
- Performance Share Unit: 19657 shares at $0 (D)
- Restricted Share Unit: 1624 shares at $0 (D)
- Restricted Share Unit: 1750 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 423239000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -43193000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 24.9892
Average Volume: 607722.43
30-Day High: 24.9892
30-Day Low: 18.65

[Detailed Financials: TTM 2024]
- Total Assets: $580,553,000.00
- Total Liabilities: $142,117,000.00
- Total Equity: $438,436,000.00
- Current Assets: $331,799,000.00
- Current Liabilities: $100,621,000.00

[Income Statement: TTM 2024]
- Revenue: $423,239,000.00
- Net Income: $-43,193,000.00
- Gross Profit: $362,329,000.00
- Operating Income: $-45,616,000.00
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $75,627,000.00

[Detailed Financials: FY 2024]
- Total Assets: $580,553,000.00
- Total Liabilities: $142,117,000.00
- Total Equity: $438,436,000.00
- Current Assets: $331,799,000.00
- Current Liabilities: $100,621,000.00

[Income Statement: FY 2024]
- Revenue: $423,239,000.00
- Net Income: $-43,193,000.00
- Gross Profit: $362,329,000.00
- Operating Income: $-45,616,000.00
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $75,627,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Kiniksa Pharmaceuticals International (KNSA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Kiniksa Pharmaceuticals International.

2) MARKET_SCORE[]
This conversation was initiated because KNSA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for KNSA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, KNSA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect KNSA to increase 50% from its current price of $18.53, say: PRICE_TARGET[27.8]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Kiniksa Pharmaceuticals International.

11) ETHICAL_RATING[]
Rate Kiniksa Pharmaceuticals International’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Kiniksa Pharmaceuticals International.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

KNSA_IN_33 [2025-04-29 09:58:21 -0400] 126 Bytes | 29 tokens | Cum: 8195 tkns (102.44% of 8k)
==========================================================================

====================================
[2025-04-29 09:58:21] # Analysis Completed
Elapsed Time: 19.22 seconds